Long-term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions

Journal of the European Academy of Dermatology and Venereology

Volumn 28, Issue 11, 2014, Pages 1514-1521

  Spertino, J ^a   Lopez Ferrer A ^a   Vilarrasa, E ^a   Puig, L ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; ISONIAZID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PSORALEN; USTEKINUMAB; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY TITER; ARTHRALGIA; BACKACHE; BACTERIAL SKIN DISEASE; BASAL CELL CARCINOMA; BIOLOGICAL THERAPY; BODY MASS; BODY TEMPERATURE; CHEMOPROPHYLAXIS; CHEST TIGHTNESS; CHOLESTEATOMA; CLINICAL EVALUATION; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DIABETES MELLITUS; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; FACE ERYTHEMA; FEMALE; FEVER; FIBROMYALGIA; FLUSHING; FOLLOW UP; GASTROENTERITIS; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOTENSION; INFUSION RELATED REACTION; KNEE PROSTHESIS; LARGE CELL LUNG CARCINOMA; LATENT TUBERCULOSIS; LEUKOPLAKIA; LONG TERM SURVIVAL; LUNG TUBERCULOSIS; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; MYALGIA; MYCOBACTERIUM TUBERCULOSIS TEST KIT; NAUSEA; OBESITY; OTITIS; PARAPROTEINEMIA; PHOTOTHERAPY; PRIORITY JOURNAL; PROSTHESIS INFECTION; PRURITUS; PSORIASIS; PSORIASIS VULGARIS; RETROSPECTIVE STUDY; REVIEW; RIGOR; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; STRIDOR; SURVIVAL RATE; SURVIVAL TIME; SWEATING; SYSTEMIC THERAPY; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; TREATMENT DURATION; TUBERCULIN TEST; ULTRAVIOLET A RADIATION; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VAGINA CANDIDIASIS; VIRAL SKIN DISEASE; WHEEZING; ADOLESCENT; ADVERSE EFFECTS; COHORT ANALYSIS; COMPLICATION; DOSE RESPONSE; DRUG COMBINATION; INFUSION PUMP; KAPLAN MEIER METHOD; LONGITUDINAL STUDY; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; COHORT STUDIES; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSION PUMPS; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MALE; METHOTREXATE; MIDDLE AGED; MODELS, STATISTICAL; OBESITY; PSORIASIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84890290251     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12331     Document Type: Review

References (29)

1. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367–1374.
2. Menter A, Feldman SR, Weinstein GD et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56:31: e1–e15.
3. Puig L, Sáez E, Lozano MJ et al. Grupo español de psoriasis de la academia española de dermatología y venereología. reactions to infliximab infusions in dermatologic patients: consensus statement and treatment protocol. working group of the grupo español de psoriasis de la academia española de dermatología y venereología. Actas Dermosifiliogr 2009; 100: 103–112.
4. Elliott RA, Barber N, Horne R. Cost-effectiveness of adherence enhancing interventions: a quality assessment of the evidence. Ann Pharmacother 2005; 39: 508–515.
5. Kalb RE, Gurske J. Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo. J Am Acad Dermatol 2005; 53: 616–622.
6. Antoniou C, Stefanaki I, Stratigos A et al. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre. Br J Dermatol 2010; 162: 1117–1123.
7. Gniadecki R, Kragballe K, Dam TN, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011; 164: 1091–1096.
8. Mehren CR, Gniadecki R. Dose-creep of Infliximab during psoriasis treatment: an observational study. Acta Derm Venereol 2012; 92: 355–357.
9. Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007; 46: 645–660.
10. Garcês S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2013; 72: 1947–1955.
11. Krathen RA, Berthelot CN, Hsu S. Sustained efficacy and safety of infliximab in psoriasis: a retrospective study of 73 patients. J Drugs Dermatol 2006; 5: 251–254.
12. Escande H, Livideanu CB, Steiner A et al. Incidence and risk factors for treatment failure with infliximab in psoriasis. J Eur Acad Dermatol Venereol 2013; 27: 1323–1324.
13. Reich K, Griffiths C, Barker J et al. Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus. Dermatology 2008; 217: 268–275.
14. Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol 2011; 25: 1007–1011.
15. Pink AE, Fonia A, Allen MH, Smith CH, Barker JN. Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study. Br J Dermatol 2010; 162: 780–785.
16. Hoffmann JH, Hartmann M, Enk AH, Hadaschik EN. Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction. Br J Dermatol 2011; 165: 1355–1358.
17. Esposito M, Gisondi P, Cassano N et al. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol 2013; 169: 666–672.
18. Glintborg B, Østergaard M, Dreyer L et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011; 63: 382–390.
19. Di Lernia V, Tasin L, Pellicano R, Zumiani G, Albertini G. Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis. J Dermatolog Treat 2012; 23: 404–409.
20. Gisondi P, Tessari G, Di Mercurio M, Del Giglio M, Girolomoni G. Retention rate of systemic drugs in patients with chronic plaque psoriasis. Clinical Dermatology 2013; 1: 8–14.
21. Naldi L, Addis A, Chimenti S et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatology 2008; 217: 365–373.
22. Duarte AA, Chehin FB. Moderate to severe psoriasis treated with infliximab -53 patients: patients profile, efficacy and adverse effects. An Bras Dermatol 2011; 86: 257–263.
23. Gremese E, Carletto A, Padovan M et al. Gruppo Italiano di Studio sulle Early Arthritis (GISEA). Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res (Hoboken) 2013; 65: 94–100.
24. Ottaviani S, Allanore Y, Tubach F et al. Body mass indexinfluences the response to infliximab in ankylosing spondylitis. Arthritis Res Ther 2012; 14: R115.
25. di Minno MN, Peluso R, Iervolino S et al. Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res (Hoboken) 2013; 65: 141–147.
26. Di Minno MN, Peluso R, Iervolino S, Russolillo A, Lupoli R, Scarpa R; on behalf of the CaRRDs Study Group. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann Rheum Dis. 2013; 14. [Epub ahead of print].
27. Puig L. Anti-tumour necrosis factor-α treatment and weight gain in psoriasis: the ‘pudgy blanching’ conundrum. Br J Dermatol 2013; 168: 923–924.
28. Wee JS, Petrof G, Jackson K, Barker JN, Smith CH. Infliximab for the treatment of psoriasis in the U.K.: 9 years’ experience of infusion reactions at a single centre. Br J Dermatol 2012; 167: 411–416.
29. Moss AC, Fernandez-Becker N, Jo Kim K, Cury D, Cheifetz AS. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease. Aliment Pharmacol Ther 2008; 28: 221–227.